Hormonal regulation of breast cancer growth

By | October 20, 2011

How growth hormone regulation in breast cancer? Mammary gland growth, development and cell proliferation is governed by estrogen and progesterone regulation. It is present in breast epithelial tissue through the estrogen receptor and progesterone receptor can be achieved. Therefore, the amount of the receptor content, determines the size of its hormonal responses. The hormone receptor complex with a nucleus cell interaction is the key effect of hormones normal breast epithelial cells exist in estrogen and progesterone receptors, when cells become cancerous, the estrogen and progesterone by the experience that some or all of the lost. If the cancer remains receptor, the growth and proliferation of breast cancer is still under endocrine regulation, known as hormone-dependent breast cancer. If the cell loss of the receptor, the growth and proliferation of breast cancer will no longer be subject to endocrine regulation, known as non-hormone-dependent breast cancer. Which accounts for about 50% of all breast cancer – 60%.
How growth hormone regulation in breast cancer?
Detection of estrogen and progesterone receptors in the clinical significance:
Breast cancer prognosis of growth hormone regulation : estrogen and progesterone receptor-positive breast choke. generally well differentiated, slow development, low degree of malignancy. Otherwise poorly differentiated invasive stronger, faster development, higher degree of Cyprus. Large number of clinical data confirm that estrogen and progesterone receptor-positive breast cancer patients better prognosis than negative, and poor high rate of recurrence of less;
growth hormone regulation in breast cancer endocrine therapy based on reasonable: endocrine therapy for breast cancer more than hormone-dependent breast cancer for patients. According to the literature, pure estrogen receptor-positive patients, endocrine therapy efficiency up to 50% – 60%, estrogen and progesterone receptors are positive have efficiencies as high as 80%. Estrogen and progesterone receptors were negative in only about 10% efficient. Endocrine therapy blindly about 30% efficiency. Also the effect of endocrine therapy of estrogen and progesterone receptor levels were positively correlated, the higher the receptor level, the better its efficacy.
Human epidermal growth factor receptor (HER) family is a group of transmembrane receptors, including four members of the family that is HER-1, HER-2, HER-3 and HER-4. Preclinical studies suggest that, HER-2 overexpression is an early event in tumor formation, tumor growth through cell cycle plays an important role in the process. HER-1 overexpression in the process of tumor development is relatively late event. At the same time the expression of HER-1 and HER-2 breast cancer, suggesting that resistance to endocrine therapy on relapse and easy. HER-2 in about 25% to 30% of highly expressed in breast cancer, HER-2 over-expression and resistance to hormone therapy, and so on doxorubicin is not sensitive to chemotherapy and poor prognosis.

Leave a Reply

Your email address will not be published. Required fields are marked *